CEO Ivor Elrifi Acquires 667,000 Shares at $1.00, Lifting Stake to 4.47 Million
TLSA is trading near its 52-week low of $0.866 (10% above the low) on elevated volume (11× avg).
Summary
CEO Ivor Elrifi bought 667,000 shares at $1.00, a $667,000 investment, increasing his total holdings to 4.47 million shares. The purchase follows positive Phase 2 data and the Executive Chairman's recent buy, reinforcing insider conviction.
Key Events · Ownership and Investor Activity · TLSA
-
CEO Purchases 667,000 Shares
CEO Ivor Elrifi bought 667,000 shares at $1.00 per share, a $667,000 investment, bringing his total holdings to 4,472,261 shares.
-
Insider Buying Cluster
This purchase follows Executive Chairman Gabriele Cerrone's acquisition of 42,357 shares at $0.99 on July 22, indicating coordinated insider confidence.
-
Clinical Momentum Backdrop
The purchase comes after positive Phase 2 foralumab data in MS and MSA, including a 34% reduction in neuroinflammation in the third MSA patient reported on July 31.
Analysis · TLSA · Life Sciences
CEO Ivor Elrifi invested $667,000 out-of-pocket to purchase 667,000 shares at $1.00 per share. This move follows the Executive Chairman's acquisition of 42,357 shares at $0.99 on July 22, signaling coordinated insider confidence. The purchase comes amid a series of positive Phase 2 foralumab data readouts in MS and MSA, suggesting management sees the recent clinical momentum as undervalued.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLSA was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124.4M. The 52-week trading range was $0.87 to $2.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.